Dimitris Voliotis

All filings by Dimitris Voliotis on record concern Zentalis Pharmaceuticals, Inc., in the capacity of senior executive. Between 11 February 2021 and 14 February 2022, the trades on record add up to 16 filings.

The open-market record consists of 11 sales worth €1.6M, with no purchase. Outside the open market, there are 2 share grants and 3 option exercises. So far in 2022, the count stands at no purchases and 11 sales.

On 14 February 2022 came the latest disclosure, an open-market sale for €24k in Zentalis Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.